14 Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin  glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–55. 15 Nauck M, Frid A, Hermansen K, et al. Eﬃ   cacy and safety comparison  of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide eﬀ  ect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84–90. 16 Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human  GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–78. 17 Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus